Zacks overhauled shares of Antares Pharma (NASDAQ:ATRS) from a hold rating to a solid purchase rating in an exploration report distributed on Monday morning, petroglobalnews24.com reports. Zacks presently has $1.75 target cost on the claim to fame pharmaceutical organization's stock.
As per Zacks, "Antares Pharma, Inc. creates, popularizes and showcases novel conveyance arrangements, including without needle and scaled down needle injector frameworks, gel advancements and transdermal items, which enhance both the productivity of medication treatments and the personal satisfaction for patients. The Company right now disperses its without needle injector frameworks for the conveyance of insulin and development hormone in more than 20 nations and an estradiol transdermal patch for hormone substitution treatment. "
Independently, Oppenheimer restated a purchase rating and set a $4.00 target cost on shares of Antares Pharma in an examination report on Friday, September 25th. Four venture investigators have appraised the stock with a purchase rating and one has relegated a solid purchase rating to the stock. The stock has a normal rating of Buy and a normal value focus of $3.65.
Shares of Antares Pharma (NASDAQ:ATRS) exchanged down 1.87% amid exchanging on Monday, achieving $1.57. 349,514 shares of the organization's stock were traded. The company's business sector top is $243.05 million. The stock has a 50-day moving normal cost of $1.77 and a 200 day moving normal cost of $2.16. Antares Pharma has a 12 month low of $1.50 and a 12 month high of $3.04.
Antares Pharma (NASDAQ:ATRS) last discharged its quarterly profit information on Monday, August tenth. The claim to fame pharmaceutical organization reported ($0.01) income per offer for the quarter, beating experts' accord assessments of ($0.03) by $0.02. The firm had income of $14.40 million for the quarter, contrasted with the accord evaluation of $10.93 million. Amid the same quarter in the earlier year, the business posted ($0.07) profit per offer. Overall, examiners conjecture that Antares Pharma will post ($0.13) EPS for the present year.
In related news, insider James E. Flynn sold 231,793 shares of the organization's stock in an exchange dated Monday, July twentieth. The shares were sold at a normal cost of $2.17, for an aggregate estimation of $502,990.81. The exchange was revealed in a report recorded with the Securities and Exchange Commission, which is accessible through the SEC site. Likewise, real shareholder James E. Flynn sold 1,353,483 shares of the organization's stock in an exchange dated Monday, September 28th. The stock was sold at a normal cost of $1.81, for an aggregate exchange of $2,449,804.23. The exposure for this deal can be found here.
Antares Pharma, Inc. (NASDAQ:ATRS) is a strength pharmaceutical Company that spotlights on creating and commercializing self-directed parenteral pharmaceutical items and advancements. The Company creates and produces for itself and with accomplices, weight helped injectors, with and without needles, which permit patients to self-infuse drugs. It has created varieties of the without needle injector by adding a little protected needle to a pre-filled, single-use expendable injector, called the Vibex weight helped auto infusion framework. This framework is an other option to the sans needle framework for use with injectable medications in unit measurements holders and is reasonable for marked and bland injectables. It has additionally built up an expendable multi-measurements pen injector for use with standard cartridges.
To get a free duplicate of the exploration report on Antares Pharma (ATRS), click here. For more data about examination offerings from Zacks Investment Research, visit Zacks.com
Get News and Ratings for Antares Pharma Daily – Enter your email address beneath to get a brief every day outline of the most recent news and investigators' evaluations for Antares Pharma and related organizations with petroglobalnews24.com's FREE day by day email pamphlet.
As per Zacks, "Antares Pharma, Inc. creates, popularizes and showcases novel conveyance arrangements, including without needle and scaled down needle injector frameworks, gel advancements and transdermal items, which enhance both the productivity of medication treatments and the personal satisfaction for patients. The Company right now disperses its without needle injector frameworks for the conveyance of insulin and development hormone in more than 20 nations and an estradiol transdermal patch for hormone substitution treatment. "
Independently, Oppenheimer restated a purchase rating and set a $4.00 target cost on shares of Antares Pharma in an examination report on Friday, September 25th. Four venture investigators have appraised the stock with a purchase rating and one has relegated a solid purchase rating to the stock. The stock has a normal rating of Buy and a normal value focus of $3.65.
Shares of Antares Pharma (NASDAQ:ATRS) exchanged down 1.87% amid exchanging on Monday, achieving $1.57. 349,514 shares of the organization's stock were traded. The company's business sector top is $243.05 million. The stock has a 50-day moving normal cost of $1.77 and a 200 day moving normal cost of $2.16. Antares Pharma has a 12 month low of $1.50 and a 12 month high of $3.04.
Antares Pharma (NASDAQ:ATRS) last discharged its quarterly profit information on Monday, August tenth. The claim to fame pharmaceutical organization reported ($0.01) income per offer for the quarter, beating experts' accord assessments of ($0.03) by $0.02. The firm had income of $14.40 million for the quarter, contrasted with the accord evaluation of $10.93 million. Amid the same quarter in the earlier year, the business posted ($0.07) profit per offer. Overall, examiners conjecture that Antares Pharma will post ($0.13) EPS for the present year.
In related news, insider James E. Flynn sold 231,793 shares of the organization's stock in an exchange dated Monday, July twentieth. The shares were sold at a normal cost of $2.17, for an aggregate estimation of $502,990.81. The exchange was revealed in a report recorded with the Securities and Exchange Commission, which is accessible through the SEC site. Likewise, real shareholder James E. Flynn sold 1,353,483 shares of the organization's stock in an exchange dated Monday, September 28th. The stock was sold at a normal cost of $1.81, for an aggregate exchange of $2,449,804.23. The exposure for this deal can be found here.
Antares Pharma, Inc. (NASDAQ:ATRS) is a strength pharmaceutical Company that spotlights on creating and commercializing self-directed parenteral pharmaceutical items and advancements. The Company creates and produces for itself and with accomplices, weight helped injectors, with and without needles, which permit patients to self-infuse drugs. It has created varieties of the without needle injector by adding a little protected needle to a pre-filled, single-use expendable injector, called the Vibex weight helped auto infusion framework. This framework is an other option to the sans needle framework for use with injectable medications in unit measurements holders and is reasonable for marked and bland injectables. It has additionally built up an expendable multi-measurements pen injector for use with standard cartridges.
To get a free duplicate of the exploration report on Antares Pharma (ATRS), click here. For more data about examination offerings from Zacks Investment Research, visit Zacks.com
Get News and Ratings for Antares Pharma Daily – Enter your email address beneath to get a brief every day outline of the most recent news and investigators' evaluations for Antares Pharma and related organizations with petroglobalnews24.com's FREE day by day email pamphlet.
No comments:
Post a Comment
Note: only a member of this blog may post a comment.